Monique Wapenaar
Overview
Explore the profile of Monique Wapenaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hendriks P, van Thor M, Wapenaar M, Chandoesing P, van den Toorn L, van den Bosch A, et al.
Respir Med
. 2021 Jul;
186:106525.
PMID: 34218166
Background: Health-related quality of life (HRQoL) is impaired in patients with pulmonary hypertension (PH). The EmPHasis-10 and CAMPHOR questionnaires are developed to evaluate HRQoL specifically in patients with PH. Data...
2.
Wapenaar M, Bendstrup E, Molina-Molina M, Stessel M, Huremovic J, Bakker E, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2020 Oct;
37(2):192-202.
PMID: 33093783
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of pulmonary function and exercise capacity, leading to loss of quality of life and often social isolation. A new walking aid,...
3.
Koudstaal T, Wapenaar M, Van Ranst D, Beesems R, van den Toorn L, van den Bosch A, et al.
J Cardiopulm Rehabil Prev
. 2019 Oct;
39(6):397-402.
PMID: 31592929
Purpose: Pulmonary arterial hypertension (PAH) is characterized by right ventricular failure, leading to exertional dyspnea, skeletal muscle weakness, and poor quality of life (QOL). Apart from treatment with PAH-specific drugs,...
4.
Wapenaar M, Miedema J, Lammering C, Mertens F, Wijsenbeek M
Eur Respir J
. 2019 Feb;
53(2).
PMID: 30760543
No abstract available.
5.
Broos C, Wapenaar M, Looman C, In t Veen J, van den Toorn L, Overbeek M, et al.
Eur Respir J
. 2018 Jan;
51(1).
PMID: 29348185
No abstract available.
6.
Broos C, Poell L, Looman C, In t Veen J, Grootenboers M, Heller R, et al.
Respir Med
. 2017 Nov;
138S:S31-S37.
PMID: 29137908
Background: Prednisone is used as first-line therapy for pulmonary sarcoidosis. What dosing strategy has the best balance between effect and side-effects is largely unknown. We analyzed change in forced vital...
7.
van Manen M, Birring S, Vancheri C, Vindigni V, Renzoni E, Russell A, et al.
Eur Respir J
. 2017 Oct;
50(4).
PMID: 29051272
No abstract available.
8.
Wapenaar M, Patel A, Birring S, van Domburg R, Bakker E, Vindigni V, et al.
Chron Respir Dis
. 2016 Dec;
14(2):140-150.
PMID: 28019103
No disease-specific instruments exist in Dutch, French, Italian, and Swedish to measure health status in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The King's Brief Interstitial Lung...
9.
van Manen M, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2016 Apr;
33(1):75-82.
PMID: 27055839
Background: The King's Sarcoidosis Questionnaire (KSQ) is a brief questionnaire assessing health status using five modules (General Health Status, Lung, Eyes, Skin, Medication) in patients with sarcoidosis. The KSQ was...